Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Issue 10 (11th July 2022)

• Record Type: Journal Article
• Authors: Bai, Ke; Norberg, Scott M.; Sievers, Cem; Meyer, Tanya; Friedman, Jay; Hinrichs, Christian; Allen, Clint T.
• Is Part Of: Head & neck. Volume 44:Issue 10(2022)
• Page Start: E31
• Page End: E37
• Publication Date: 2022-07-11
• Subjects: human papillomavirus type 6 -- immune checkpoint blockade -- PD‐L1 -- recurrent respiratory papillomatosis -- resident memory T cell; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.27144
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: Immune checkpoint blockade can provide clinical benefit for patients with advanced cancer. Here, we report durable disease control over many years following PD‐L1 blockade through induction of a viral antigen‐specific T cell response in an adult patient with recurrent respiratory papillomatosis. Methods: Antigen‐specific T cell response assays, single cell RNA‐sequencing, and RNA‐scope was used to study clinical tissues. Results: An HPV6 E2‐specific T cell clone restricted to HLA‐B*55, present at low frequency in the pre‐treatment papilloma, significantly expanded after six doses of PD‐L1 blockade and remained present and functional at the site of initial response in the larynx as a tissue resident memory T cell for 4 years. An associated reduction in E2 target gene was observed following treatment. Conclusions: Although demonstrated in a single exceptional responder, these results highlight that immune checkpoint blockade may induce durable, viral antigen‐specific immunity of sufficient magnitude to control disease in patients with nonmalignant disorders.